- The guideline states there is “high-certainty evidence that nicotine e-cigarettes improve quit rates versus NRT”
- It says public health bodies agree that “regulated e-cigarettes are significantly less harmful than smoking and effective for quitting in dependent smokers, with minimal risk to bystanders”
- A large network meta-analysis found nicotine vapes were “associated with the greatest chances of quitting tobacco smoking at six months or longer”
- The stated primary goal of treatment is “permanent smoking cessation”
UK addiction specialists have formally endorsed vapes as an effective stop-smoking aid in new clinical guidelines on the pharmacological management of substance dependence.
The evidence-based consensus guideline, published in the Journal of Psychopharmacology, reviews the latest research on treatments for nicotine and other substance dependence.
It brings together international experts, including UK clinicians, to produce “up-to-date, evidence-based recommendations covering the pharmacological management of substance dependence”.
When it comes to smoking, the document states that quitting tobacco remains the central aim. “The primary goal of treatment is permanent smoking cessation,” it says. It adds that “An abstinent period of six months or longer is considered a marker of success.”
But the route to that goal can include harm reduction – and that is where vapes feature prominently.
High-certainty evidence on quitting
Under the section on harm reduction, the guideline defines vapes as devices that “heat a liquid to produce an inhalable aerosol to deliver nicotine without tobacco combustion and are widely used in quit attempts.”
It cites a major Cochrane review of 90 studies, including 27 randomised controlled trials involving more than 13,000 participants. The finding is there is “high-certainty evidence that nicotine e-cigarettes improve quit rates versus NRT (RR 1.63) or non-nicotine e-cigarettes (RR 1.94)”.
In other words, nicotine vapes outperform traditional nicotine replacement therapy such as patches or gum, as well as non-nicotine devices, when it comes to helping smokers quit.
The guideline goes further, referencing a large component network meta-analysis of 332 RCTs involving 157,179 participants. This analysis found that “Nicotine e-cigarettes, varenicline and cytisine were associated with the greatest chances of quitting tobacco smoking at six months or longer, with no clear evidence of a difference in effectiveness between the three.”
That places vapes alongside the most effective licensed stop-smoking medications.
Less harmful than smoking
The document also addresses relative risk. Drawing on multiple reviews, it states: “Based on multiple reviews, public health bodies agree that regulated e-cigarettes are significantly less harmful than smoking and effective for quitting in dependent smokers, with minimal risk to bystanders.”
It adds an important caveat, that “Any smoking is harmful, so people who smoke and vape concurrently should be encouraged to stop smoking entirely.”
For people who have never smoked, the advice is: “Those who have never smoked should avoid starting either.” But for smokers considering switching, the guideline says: “If someone chooses to start using nicotine, e-cigarettes are less harmful than smoking.”
It acknowledges uncertainty about long-term effects but notes that “biomarker studies suggest far lower risk than cigarettes.”
Supporting smokers to switch
The guideline includes practical advice for clinicians helping smokers transition away from combustible tobacco.
“Transitioning from smoking tobacco to vaping nicotine involves selecting a suitable nicotine strength, flavour, and propylene glycol/vegetable glycerine ratio to manage cravings and support cessation,” it explains.
It also notes that “Flavour variety can help initiate switching, and non-tobacco flavours are associated with higher quit success.”
In the UK and EU, nicotine concentration is regulated. It says: “In the UK, EU, and some other countries, e-liquids are capped at 20 mg/mL nicotine.”
Side effects are acknowledged but described as generally mild. “Side effects such as throat irritation, cough and nausea are common but usually mild and short-lived,” it says.
The guideline also highlights an important pharmacological distinction – while smoking induces certain liver enzymes because of exposure to toxic compounds in smoke, “NRT, e-cigarettes, and other non-combustible products do not induce CYPIA2.” That difference can be clinically relevant for patients taking medicines affected by smoking.
Tackling misconceptions about nicotine
The authors point to a persistent barrier to quitting – confusion about nicotine itself.
“Misconceptions about nicotine’s harm remain a barrier to treatment uptake,” the guideline says. It adds: “Clinicians play a key role in correcting these beliefs.”
Nicotine replacement therapy is described as delivering nicotine “slowly and at lower peak levels, with minimal risk, even with long-term use.” Vapes and oral nicotine pouches “deliver nicotine more efficiently than NRT, and depending on dose and duration of use, comparable levels to tobacco cigarettes.”
But the central distinction remains combustion. Vapes deliver nicotine “without tobacco combustion” – the process responsible for the vast majority of smoking-related disease.
Harm reduction within a broader treatment plan
The guideline says that pharmacotherapy should sit alongside behavioural support. It says: “Behavioural support from a trained advisor alongside pharmacotherapy improves quit success.”
It also emphasises shared decision-making, saying: “It is essential that both the prescriber and individual are aware of, and agree, the goal of treatment, what it hopes to achieve, and in what time frame.”
For smokers unable or unwilling to quit nicotine entirely, the message from UK addiction doctors is that switching from combustible tobacco to regulated vapes is an evidence-based option.
The end goal remains permanent smoking cessation. But in these new clinical guidelines, vapes are firmly positioned as one of the most effective tools currently available to help dependent smokers get there.
ends
